Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Target Raised at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by equities researchers at Royal Bank Of Canada from $737.00 to $810.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 10.77% from the company’s previous close.

Several other research firms have also recently commented on REGN. Citigroup increased their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Leerink Partners raised their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Argus upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a research note on Thursday, October 1st. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $817.92.

Regeneron Pharmaceuticals Stock Down 1.5%

Shares of REGN traded down $10.89 on Thursday, reaching $731.23. The stock had a trading volume of 32,070 shares, compared to its average volume of 823,642. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The firm has a market capitalization of $75.29 billion, a price-to-earnings ratio of 18.05, a price-to-earnings-growth ratio of 1.41 and a beta of 0.16. The company has a 50-day simple moving average of $791.29 and a 200-day simple moving average of $720.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals will post 45.37 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock worth $3,302,458 in the last quarter. 6.97% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in REGN. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $29,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.